Related Experiment Video
Updated: May 10, 2026
Analyzing the α-Actinin Network in Human iPSC-Derived Cardiomyocytes Using Single Molecule Localization Microscopy
Published on: November 3, 2020
Cardiac α-actin over-expression therapy in dominant ACTA1 disease
Insights
Overexpressing cardiac actin in mice with dominant ACTA1 skeletal muscle disease reduced lethality in one model. This suggests cardiac actin may be a therapeutic for some ACTA1 mutations.
Area of Science:
- Genetics and Molecular Biology
- Muscle Physiology
- Disease Modeling
Background:
- Over 200 mutations in the skeletal muscle α-actin gene (ACTA1) cause dominant or recessive skeletal muscle diseases.
- Currently, no specific therapies exist for ACTA1-related myopathies.
- Cardiac α-actin, highly similar to skeletal α-actin, is the primary fetal actin isoform and can substitute for skeletal actin in mouse models of recessive ACTA1 disease.
Purpose of the Study:
- To investigate if transgenic cardiac α-actin overexpression in postnatal skeletal muscle can ameliorate phenotypes in mouse models of severe dominant ACTA1 disease.
- To assess the therapeutic potential of cardiac α-actin for dominant ACTA1 mutations.
Main Methods:
- Utilized mouse models of severe dominant ACTA1 disease (ACTA1(D286G).Acta1(+/-) and Acta1(H40Y)).
- Introduced transgenic cardiac α-actin overexpression in postnatal skeletal muscle.
- Monitored survival rates and phenotypic severity.
Main Results:
- Cardiac α-actin transgene significantly reduced lethality in ACTA1(D286G).Acta1(+/-) mice (from ~59% to ~12% before 30 days).
- The cardiac α-actin transgene did not significantly improve survival in Acta1(H40Y) mice, where ~80% of males die by 5 months.
- Acta1(H40Y) mice exhibited endogenously elevated cardiac α-actin levels in skeletal muscle, a novel finding.
Conclusions:
- Transgenic cardiac α-actin overexpression shows therapeutic potential for at least some dominant ACTA1 mutations.
- The lack of efficacy in Acta1(H40Y) mice may be related to endogenous cardiac α-actin levels.
- Further research is needed to understand the precise mechanisms and patient applicability.
Abstract:
More than 200 mutations in the skeletal muscle α-actin gene (ACTA1) cause either dominant or recessive skeletal muscle disease. Currently, there are no specific therapies. Cardiac α-actin is 99% identical to skeletal muscle α-actin and the predominant actin isoform in fetal muscle. We previously showed cardiac α-actin can substitute for skeletal muscle α-actin, preventing the early postnatal death of Acta1 knock-out mice, which model recessive ACTA1 disease. Dominant ACTA1 disease is caused by the presence of 'poison' mutant actin protein. Experimental and anecdotal evidence nevertheless indicates that the severity of dominant ACTA1 disease is modulated by the relative amount of mutant skeletal muscle α-actin protein present. Thus, we investigated whether transgenic over-expression of cardiac α-actin in postnatal skeletal muscle could ameliorate the phenotype of mouse models of severe dominant ACTA1 disease. In one model, lethality of ACTA1(D286G). Acta1(+/-) mice was reduced from ∼59% before 30 days of age to ∼12%. In the other model, Acta1(H40Y), in which ∼80% of male mice die by 5 months of age, the cardiac α-actin transgene did not significantly improve survival. Hence cardiac α-actin over-expression is likely to be therapeutic for at least some dominant ACTA1 mutations. The reason cardiac α-actin was not effective in the Acta1(H40Y) mice is uncertain. We showed that the Acta1(H40Y) mice had endogenously elevated levels of cardiac α-actin in skeletal muscles, a finding not reported in dominant ACTA1 patients.
Related Concept Videos
01:13Actin Polymerization and Cell Motility
Actin cytoskeleton dynamics can produce pushing, pulling, and resistance forces that help the cell to migrate.
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
01:25Aortic Regurgitation III: Medical Management